SNDX - NASDAQ
Syndax Pharmaceuticals, Inc.
$18.34
-2.7%Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
At a Glance
Live SnapshotSyndax Pharmaceuticals, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Syndax Pharmaceuticals, Inc. Income Statement
SNDX • NASDAQ
| Syndax Pharmaceuticals, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||||||||
172.4M | 23.7M | 0.0 | 0.0 | 139.7M | 1.5M | 1.5M | 1.5M | 2.1M | 1.2M | 627K | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | |||||||||||||||
(7M) | (826K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (51K) | |
165.4M | 22.9M | 0.0 | 0.0 | 139.7M | 1.5M | 1.5M | 1.5M | 2.1M | 1.2M | 627K | 0.0 | 0.0 | 0.0 | -51K | |
OPERATING INCOME | |||||||||||||||
(438.5M) | (362.5M) | (230M) | (151.8M) | (113.5M) | (72.9M) | (59.1M) | (77.4M) | (64.1M) | (45M) | (21.1M) | (21.3M) | (8.6M) | (8.7M) | (9.6M) | |
(179.7M) | (120.9M) | (66.9M) | (33.3M) | (25.2M) | (22.5M) | (16.1M) | (17.3M) | (15.9M) | (13.3M) | (11.6M) | (11.2M) | (5.4M) | (3.5M) | (3.5M) | |
(258.8M) | (241.6M) | (163M) | (118.5M) | (88.2M) | (50.4M) | (43M) | (60.1M) | (48.2M) | (31.7M) | (9.5M) | (10.2M) | (3.2M) | (5.2M) | (6.1M) | |
-273.1M | -339.7M | -230M | -151.8M | 26.2M | -71.4M | -57.5M | -75.9M | -62M | -43.8M | -20.5M | -21.3M | -8.6M | -8.7M | -9.6M | |
PRE-TAX INCOME | |||||||||||||||
(33.8M) | (4.9M) | (208K) | (3.1M) | (1.9M) | (2.4M) | (0.0) | (1.9M) | (1.4M) | (956K) | (1.6M) | (0.0) | (0.0) | (0.0) | (2M) | |
-11.1M | 21.2M | 21M | 2.7M | -1.5M | -1.5M | 1.6M | 1.9M | 1.4M | 956K | -1.4M | 0.0 | 0.0 | 0.0 | -2M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -37K | (4K) | (0.0) | -1K | (0.0) | |
-12.3M | 20.9M | 20.6M | 2.4M | -1.3M | -1.7M | 1.5M | 1.9M | 1.2M | -706K | -3.6M | 1.5M | -5.6M | -1.2M | -3.5M | |
-285.4M | -318.8M | -209.4M | -149.3M | 24.9M | -73.2M | -56M | -74M | -60.8M | -44.5M | -24.1M | -19.8M | -14.2M | -10M | -13.1M | |
NET INCOME | |||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -76K | -89K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-285.4M | -318.8M | -209.4M | -149.3M | 24.9M | -73.1M | -56M | -74M | -60.8M | -44.5M | -24.1M | -19.8M | -14.2M | -10M | -13.1M |
SEC Filings
SNDX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | April 30, 2026 | March 31, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 19, 2025 | December 18, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 03, 2025 | November 03, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 03, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 24, 2025 | October 24, 2025 | 2025 |
Related Guides
Continue your SNDX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.